Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Given Imaging Builds Esophageal Diagnostics Portfolio With Sierra Purchase

This article was originally published in The Gray Sheet

Executive Summary

Given Imaging will bolster its esophageal diagnostics portfolio with the $35 million acquisition of Sierra Scientific Instruments, announced March 22

You may also be interested in...



Capsule Endoscopy: Poised For Growth

The market for capsule endoscopy is one of the fastest growing segments in the multibillion-dollar gastrointestinal endoscopy market. The market opportunity is vast and highly underpenetrated, and an increasing number of competitors, new product innovations, and expanding indications for the technology are positioning capsule endoscopy as a market poised for growth – particularly if the technology is proven and FDA cleared for colon cancer indications.

Given Imaging results

Second quarter sales advanced 17% to $42.1 million, including $5.7 million from recently acquired Sierra Scientific Instruments, the firm reports Aug. 12. Given acquired the esophageal diagnostics marketer in March for $35 mil. (1"The Gray Sheet" March 29, 2010). Global sales of Given's PillCam SB 2 small bowel endoscopy capsules were flat, largely due to fewer procedures in the U.S. gastrointestinal market and economic instability in Europe, according to the company. As a result, the firm is now expecting full-year 2010 sales to be on the lower end of its previous $167 million-$174 million guidance. Given noted that it recently held a pre-IDE meeting with FDA regarding its PillCam COLON 2 clinical trial and that it is still planning to initiate a study in the second half of this year comparing the capsule-based system with standard colonoscopy. A 510(k) filing will follow in the second quarter of 2011, according to the company

Given Imaging results

Second quarter sales advanced 17% to $42.1 million, including $5.7 million from recently acquired Sierra Scientific Instruments, the firm reports Aug. 12. Given acquired the esophageal diagnostics marketer in March for $35 mil. (1"The Gray Sheet" March 29, 2010). Global sales of Given's PillCam SB 2 small bowel endoscopy capsules were flat, largely due to fewer procedures in the U.S. gastrointestinal market and economic instability in Europe, according to the company. As a result, the firm is now expecting full-year 2010 sales to be on the lower end of its previous $167 million-$174 million guidance. Given noted that it recently held a pre-IDE meeting with FDA regarding its PillCam COLON 2 clinical trial and that it is still planning to initiate a study in the second half of this year comparing the capsule-based system with standard colonoscopy. A 510(k) filing will follow in the second quarter of 2011, according to the company

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028673

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel